Perspective Therapeutics, Inc.
CATX · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -27.9% | -15.2% | – | – |
| Cost of Goods Sold | $1 | $1 | $1 | $0 |
| Gross Profit | -$1 | -$0 | -$0 | $0 |
| % Margin | -270.8% | -152.8% | -114% | – |
| R&D Expenses | $20 | $12 | $14 | $13 |
| G&A Expenses | $8 | $8 | $8 | $8 |
| SG&A Expenses | $8 | $8 | $8 | $8 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$1 | $4 | -$0 | $24 |
| Operating Expenses | $27 | $24 | $22 | $46 |
| Operating Income | -$28 | -$24 | -$22 | -$45 |
| % Margin | -13,330.6% | -8,289.3% | -6,383.6% | – |
| Other Income/Exp. Net | $2 | $2 | $4 | $3 |
| Pre-Tax Income | -$26 | -$22 | -$18 | -$42 |
| Tax Expense | $0 | $0 | $0 | -$2 |
| Net Income | -$26 | -$21 | -$18 | -$40 |
| % Margin | -12,425.4% | -7,408.6% | -5,314.9% | – |
| EPS | -0.35 | -0.3 | -0.25 | -0.57 |
| % Growth | -16.7% | -20% | 56.1% | – |
| EPS Diluted | -0.35 | -0.3 | -0.25 | -0.57 |
| Weighted Avg Shares Out | 74 | 71 | 72 | 71 |
| Weighted Avg Shares Out Dil | 74 | 71 | 72 | 71 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $2 | $2 | $3 |
| Interest Expense | $0 | $0 | $0 | -$0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$25 | -$21 | -$17 | -$42 |
| % Margin | -12,023.4% | -7,292.1% | -5,063.5% | – |